Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)-isopropyl ester treatment

Arch Ophthalmol. 2001 Aug;119(8):1165-70. doi: 10.1001/archopht.119.8.1165.

Abstract

Objective: To investigate the effects of topical prostaglandin F(2 alpha)--isopropyl ester (PGF(2 alpha)-IE) administration on immunoreactivity of matrix metalloproteinases (MMPs) 1, 2, and 3 within the anterior segment tissues of monkey eyes.

Methods: Eight eyes from 4 cynomolgus monkeys were evaluated. One eye from each monkey was treated with 2 mg of PGF(2 alpha)-IE twice daily for 5 days, and intraocular pressure reduction was measured. After fixation and processing, deparaffinized sections of anterior segments were immunostained using antibodies to MMP-1 (interstitial collagenase), MMP-2 (gelatinase A), or MMP-3 (stromelysin-1). Optical density along 2 line segments overlying the iris root, ciliary muscle, and adjacent sclera and perpendicular to their long axes was measured using imaging densitometry.

Results: Compared with the contralateral vehicle-treated eyes, statistically significant increases in optical density scores were observed in the iris root, ciliary muscle, and adjacent sclera for all 3 MMPs (P<.01). In these tissues, MMP-1 immunoreactivity was increased by a mean +/- SD of 89% +/- 16%, 61% +/- 8%, and 66% +/- 57%, respectively; MMP-2 immunoreactivity by 129% +/- 53%, 82% +/- 27%, and 267% +/- 210%, respectively; and MMP-3 immunoreactivity by 207% +/- 84%, 83% +/- 49%, and 726% +/- 500%, respectively.

Conclusions: Treatment of monkey eyes with PGF(2 alpha)-IE induces elevation of MMP-1, MMP-2, and MMP-3 in tissues of the uveoscleral outflow pathway. These increases suggest that MMPs might play an important role in the increased uveoscleral outflow observed with topical prostaglandin treatment.

Clinical relevance: Immunoreactivity of MMPs in tissues of the monkey uveoscleral outflow pathway is increased after topical treatment with PGF(2 alpha)-IE. This response also might be involved in the intraocular pressure--lowering effect of other prostanoids used to treat glaucoma.

MeSH terms

  • Administration, Topical
  • Animals
  • Anterior Eye Segment / drug effects*
  • Anterior Eye Segment / enzymology
  • Ciliary Body / drug effects
  • Ciliary Body / enzymology
  • Dinoprost / administration & dosage*
  • Dinoprost / analogs & derivatives
  • Immunoenzyme Techniques
  • Intraocular Pressure / drug effects
  • Iris / drug effects
  • Iris / enzymology
  • Macaca fascicularis
  • Matrix Metalloproteinase 1 / metabolism*
  • Matrix Metalloproteinase 2 / metabolism*
  • Matrix Metalloproteinase 3 / metabolism*
  • Muscle, Smooth / drug effects
  • Muscle, Smooth / enzymology
  • Ophthalmic Solutions / administration & dosage
  • Sclera / drug effects*
  • Sclera / enzymology
  • Uvea / drug effects*
  • Uvea / enzymology

Substances

  • Ophthalmic Solutions
  • prostaglandin F2 isopropyl ester
  • Dinoprost
  • Matrix Metalloproteinase 3
  • Matrix Metalloproteinase 2
  • Matrix Metalloproteinase 1